Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186. https://doi.org/10.1038/s41571-020-00447-z

Article  PubMed  Google Scholar 

Shidoh S, Savjani RR, Cho NS, Ullman HE, Hagiwara A, Raymond C, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Kaprealian TB, Salamon N, Ellingson BM (2022) Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. J Neurooncol 160:115–125. https://doi.org/10.1007/s11060-022-04123-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197. https://doi.org/10.1200/JCO.2007.14.8163

Article  PubMed  Google Scholar 

Alexiou GA, Tsiouris S, Kyritsis AP, Voulgaris S, Argyropoulou MI, Fotopoulos AD (2009) Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 95:1–11. https://doi.org/10.1007/s11060-009-9897-1

Article  PubMed  Google Scholar 

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461. https://doi.org/10.1016/S1470-2045(08)70125-6

Article  PubMed  Google Scholar 

Youssef G, Rahman R, Bay C, Wang W, Lim-Fat MJ, Arnaout O, Bi WL, Cagney DN, Chang YS, Cloughesy TF, DeSalvo M, Ellingson BM, Flood TF, Gerstner ER, Gonzalez Castro LN, Guenette JP, Kim AE, Lee EQ, McFaline-Figueroa JR, Potter CA, Reardon DA, Huang RY, Wen PY (2023) Evaluation of standard response assessment in Neuro-Oncology, modified response assessment in Neuro-Oncology, and immunotherapy response assessment in Neuro-Oncology in newly diagnosed and recurrent glioblastoma. J Clin Oncol 41:3160–3171. https://doi.org/10.1200/JCO.22.01579

Article  CAS  PubMed  Google Scholar 

Katsanos AH, Alexiou GA, Fotopoulos AD, Jabbour P, Kyritsis AP, Sioka C (2019) Performance of 18F-FDG, 11 C-Methionine, and 18F-FET PET for glioma grading: A Meta-analysis. Clin Nucl Med 44:864–869. https://doi.org/10.1097/RLU.0000000000002654

Article  PubMed  Google Scholar 

Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Ruda R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M (2024) PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol 25:e29–e41. https://doi.org/10.1016/S1470-2045(23)00525-9

Article  PubMed  PubMed Central  Google Scholar 

de Zwart PL, van Dijken BRJ, Holtman GA, Stormezand GN, Dierckx R, van Jan P, van der Hoorn A (2020) Diagnostic accuracy of PET tracers for the differentiation of tumor progression from Treatment-Related changes in High-Grade glioma: A systematic review and metaanalysis. J Nucl Med 61:498–504. https://doi.org/10.2967/jnumed.119.233809

Article  CAS  PubMed  Google Scholar 

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C (2012) MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging 39:1021–1029. https://doi.org/10.1007/s00259-012-2109-9

Article  CAS  PubMed  Google Scholar 

Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougere C (2014) Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients. J Nucl Med 55:198–203. https://doi.org/10.2967/jnumed.113.122333

Article  CAS  PubMed  Google Scholar 

Ehtesham M, Min E, Issar NM, Kasl RA, Khan IS, Thompson RC (2013) The role of the CXCR4 cell surface chemokine receptor in glioma biology. J Neurooncol 113:153–162. https://doi.org/10.1007/s11060-013-1108-4

Article  CAS  PubMed  Google Scholar 

Watts A, Singh B, Singh H, Bal A, Kaur H, Dhanota N, Arora SK, Mittal BR, Behera D (2023) [(68)Ga]Ga-Pentixafor PET/CT imaging for in vivo CXCR4 receptor mapping in different lung cancer histologic sub-types: correlation with quantitative receptors’ density by immunochemistry techniques. Eur J Nucl Med Mol Imaging 50:1216–1227. https://doi.org/10.1007/s00259-022-06059-2

Article  CAS  PubMed  Google Scholar 

Buck AK, Serfling SE, Lindner T, Hanscheid H, Schirbel A, Hahner S, Fassnacht M, Einsele H, Werner RA (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49:4133–4144. https://doi.org/10.1007/s00259-022-05849-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacobs SM, Wesseling P, de Keizer B, Tolboom N, Ververs FFT, Krijger GC, Westerman BA, Snijders TJ, Robe PA, van der Kolk AG (2022) CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather. Eur J Nucl Med Mol Imaging 49:481–491. https://doi.org/10.1007/s00259-021-05196-4

Article  CAS  PubMed  Google Scholar 

Waheed A, Singh B, Watts A, Kaur H, Singh H, Dhingra K, Ahuja C, Madan R, Singh A, Radotra BD (2024) 68 Ga-Pentixafor PET/CT for in vivo imaging of CXCR4 receptors in glioma demonstrating a potential for response assessment to radiochemotherapy: preliminary results. Clin Nucl Med 49:e141–e148. https://doi.org/10.1097/RLU.0000000000005073

Article  PubMed  Google Scholar 

Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M (2016) First experience with chemokine receptor CXCR4-Targeted PET imaging of patients with solid cancers. J Nucl Med 57:741–746. https://doi.org/10.2967/jnumed.115.161034

Article  CAS  PubMed  Google Scholar 

Yu J, Zhou X, Shen L (2023) CXCR4-Targeted radiopharmaceuticals for the imaging and therapy of malignant tumors. Molecules 28. https://doi.org/10.3390/molecules28124707

Chen Z, Yang A, Chen A, Dong J, Lin J, Huang C, Zhang J, Liu H, Zeng Z, Miao W (2024) [(68)Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 51:1926–1936. https://doi.org/10.1007/s00259-024-06621-0

Article  CAS  PubMed  Google Scholar 

Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA (2022) Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-Pentixafor PET. J Nucl Med 63:1687–1692. https://doi.org/10.2967/jnumed.121.263693

Article  CAS  PubMed  Google Scholar 

Roustaei H, Vosoughi H, Askari E, Aziz Kalantari B, Norouzbeigi N, Anvari K, Beheshti M, Aryana K (2024) [(68) Ga]Ga-CXCR4 PET/CT imaging in high-grade glioma for assessment of CXCR4 receptor expression. Eur J Radiol 180:111694. https://doi.org/10.1016/j.ejrad.2024.111694

Article  PubMed  Google Scholar 

Kesch C, Kratochwil C, Mier W, Kopka K, Giesel FL (2017) (68)Ga or (18)F for prostate Cancer imaging?? J Nucl Med 58:687–688. https://doi.org/10.2967/jnumed.117.190157

Article  PubMed  Google Scholar 

Kwon D, Lozada J, Zhang Z, Zeisler J, Poon R, Zhang C, Roxin A, Lin KS, Perrin D, Benard F (2021) High-Contrast CXCR4-Targeted (18)F-PET imaging using a potent and selective antagonist. Mol Pharm 18:187–197. https://doi.org/10.1021/acs.molpharmaceut.0c00785

Article  CAS  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M (2018) (11)C-MET PET/MRI for detection of recurrent glioma. Eur J Nucl Med Mol Imaging 45:593–601. https://doi.org/10.1007/s00259-017-3916-9

Article  CAS  PubMed  Google Scholar 

Moltoni G, Romano A, Capriotti G, Campagna G, Ascolese AM, Romano A, Dellepiane F, Minniti G, Signore A, Bozzao A (2024) ASL, DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating glioma recurrence from post-treatment changes. Radiol Med 129:1382–1393. https://doi.org/10.1007/s11547-024-01862-3

Article  PubMed  PubMed Central